Weight & metabolic
Pemvidutide
Dual GLP-1/Glucagon Agonist
An investigational dual-agonist peptide targeting both GLP-1 and glucagon receptors. Being developed by Altimmune with particular focus on metabolic liver disease alongside weight management.
Also known as: ALT-801
- Status
- Pemvidutide is in Phase 2 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~4-5 days (estimated)
- How it's taken
- Weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, Glucagon
How Pemvidutide works
Simultaneously activates GLP-1 and glucagon receptors. The GLP-1 component reduces appetite while the glucagon component increases energy expenditure and promotes fat breakdown, particularly in the liver.
What research has looked at
- Significant liver fat reduction
- Weight loss alongside liver health benefits
- Dual mechanism of action
- Promising for MASH/NAFLD patients
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Still being evaluated in trials
Sources
- Active clinical trials for pemvidutide · U.S. National Library of Medicine
- PubMed research on pemvidutide GLP-1 glucagon NASH · NIH · National Library of Medicine
- DrugBank record for pemvidutide · DrugBank
Track Pemvidutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Pemvidutide FAQ
What is Pemvidutide?
An investigational dual-agonist peptide targeting both GLP-1 and glucagon receptors. Being developed by Altimmune with particular focus on metabolic liver disease alongside weight management.
How does Pemvidutide work?
Simultaneously activates GLP-1 and glucagon receptors. The GLP-1 component reduces appetite while the glucagon component increases energy expenditure and promotes fat breakdown, particularly in the liver.
Is Pemvidutide FDA approved?
No. Pemvidutide is in Phase 2 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Pemvidutide?
Reported half-life: ~4-5 days (estimated).
How is Pemvidutide taken?
Weekly subcutaneous injection.
What side effects have been reported with Pemvidutide?
Reported in the sources: Nausea; Vomiting; Diarrhea; Decreased appetite; Still being evaluated in trials.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.